The MRI with Gadolinium Contrast Informed Consent is a ready-to-use healthcare & wellness template you can send for signature in minutes. It is written for 1 signer (patient) and, by default, expires 30 days after it is sent if left unsigned. It covers consent, radiology, mri, contrast, gadolinium, imaging. Like every Abundera Sign template it is a convenience draft structured for ESIGN Act and UETA compliance, not a substitute for legal advice. Each signed copy is sealed with PAdES-LTA digital signatures, dual RFC 3161 timestamps, and a tamper-evident evidence package in WORM storage.
Document Preview
# MRI with Gadolinium Contrast Informed Consent > **Important — not medical advice.** For use by a licensed provider; tailor risks/benefits/alternatives to the patient and your institution's protocols and state law. **Patient Name:** ___________ **Date of Birth:** ___________ **Medical Record Number:** ___________ **Ordering Physician:** ___________ **Scheduled Exam Date:** ___________ **Body Region / Study Type:** ___________ **Gadolinium Agent to be Used:** ___________ --- ## 1. Description of the Procedure Magnetic resonance imaging (MRI) is a non-ionizing imaging technique that uses strong magnetic fields and radiofrequency waves to produce detailed images of internal structures. MRI does not use X-ray radiation. A gadolinium-based contrast agent (GBCA) is an intravenous medication that improves the visibility of certain tissues, blood vessels, and abnormalities during MRI. It is administered through an IV placed in your arm or hand before or during the scan. Gadolinium shortens the relaxation time of nearby hydrogen nuclei, causing enhanced (brighter) signal in areas of increased blood supply, disrupted blood-brain barrier, or active inflammation. The exam typically takes 30–90 minutes depending on the body region and number of sequences required. **Indication(s) for contrast-enhanced MRI:** ___________ --- ## 2. Expected Benefits Gadolinium contrast significantly improves the diagnostic accuracy of MRI for many conditions, including: - Detection and characterization of brain and spinal cord tumors, metastases, demyelinating lesions (multiple sclerosis), and infections - Evaluation of post-surgical change versus tumor recurrence